Table 1. Baseline characteristics of patients and early gastric cancer and background gastric mucosa.
| n | (%) | |
|---|---|---|
| Total number of lesions | 97 | |
| Age (year), median (IQR) | 73.0 (43–92) | |
| Sex | ||
| Male | 77 | 79.4 |
| Female | 20 | 20.6 |
| Comorbidities | ||
| Hypertension | 45 | 46.4 |
| Diabetes | 20 | 20.6 |
| Reflux esophagitis | 7 | 7.2 |
| Other organ cancer | 14 | 14.4 |
| Medicine | ||
| Anti-acid drugs | 30 | 30.9 |
| Low-dose aspirin | 16 | 16.5 |
| Anticoagulants | 10 | 10.3 |
| Prednisolone | 3 | 3.1 |
| NSAIDs | 3 | 3.1 |
| H. pylori | ||
| Uninfected | 8 | 8.2 |
| Current infection | 21 | 21.6 |
| Past infection | 68 | 70.1 |
| Tumor location | ||
| U | 19 | 19.6 |
| M | 38 | 39.2 |
| L | 40 | 41.2 |
| Color | ||
| Whitish | 16 | 16.5 |
| Normal tone | 11 | 11.3 |
| Redness | 70 | 72.2 |
| Macroscopic type | ||
| 0-IIa | 19 | 19.6 |
| 0-IIb | 9 | 9.3 |
| 0-IIc | 66 | 68.0 |
| Others | 3 | 3.1 |
| Tumor size (mm), median (IQR) | 11.0 (2–30) | |
| Histological type | ||
| Undifferentiated | 6 | 6.2 |
| Moderately differentiated | 12 | 12.4 |
| Well-differentiated | 79 | 81.4 |
| Endoscopic atrophy | ||
| None | 5 | 5.2 |
| Mild (C-1, C-2) | 9 | 9.3 |
| Moderate (C-3, O-1) | 31 | 32.0 |
| Severe (O-2, O-3) | 52 | 53.6 |
| Endoscopic intestinal metaplasia | ||
| None | 25 | 25.8 |
| Patchy | 18 | 18.6 |
| Partial | 29 | 29.9 |
| Overall | 25 | 25.8 |
| Map-like redness | ||
| None | 58 | 59.8 |
| Patchy | 7 | 7.2 |
| Partial | 26 | 26.8 |
| Overall | 6 | 6.2 |
Data were presented as number (percentage) of patients unless otherwise indicated. Data for age and tumor size are presented as median. IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs.